While defined targeted therapeutic strategies have been developed for patients with ER+/PR+ and HER2+ diseases, chemotherapy is currently the mainstay of systemic treatment for triple-negative (ER−/PR−/HER2−) breast cancer (TNBC) patients, which represents approximately 20% of all breast cancers [2]. Here, ESR1 is linked to breast cancer.